Edwards Lifesciences (EW) Experiences Rubust Heart Valve Sales, Analyst Sees Upside
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Edwards Lifesciences Corp. (EW) Tops Q4 EPS by 13c; Guides Q1, FY13
February 4, 2013 4:02 PM ESTEdwards Lifesciences Corp. (NYSE: EW) reported Q4 EPS of $0.90, $0.13 better than the analyst estimate of $0.77. Revenue for the quarter came in at $510.5 million versus the consensus estimate of $499.46 million.
Edwards Lifesciences Corp. sees FY2013 EPS of $3.21-3.31, versus the consensus of $3.27. Edwards... More
